Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    Canavan Disease
Previous Study | Return to List | Next Study

Natural History Study of Patients With Canavan Disease, CAN Inform

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04126005
Recruitment Status : Recruiting
First Posted : October 14, 2019
Last Update Posted : October 31, 2019
Sponsor:
Information provided by (Responsible Party):
Aspa Therapeutics

Brief Summary:
This is study will use medical records that will allow retrospective data extraction of critical milestone and motor function data. In addition, prospective assessments will collect data relevant to the natural history of Canavan disease in children.

Condition or disease
Canavan Disease

Detailed Description:
CANInform, the Canavan disease natural history study, will be the first multinational effort to rigorously gather both retrospective and prospective data from this patient population. Data collection will include extraction of retrospective data from medical records of living patients and deceased patients, and collection of prospective, longitudinal data from living patients and their parent(s)/caregiver(s). Motor function assessments will be performed in the home by qualified study team members. In addition, families will be invited to attend clinic visits or will be followed by the clinical site remotely for up to 3 years.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease
Actual Study Start Date : October 10, 2019
Estimated Primary Completion Date : September 20, 2022
Estimated Study Completion Date : September 20, 2022


Group/Cohort
Cohort 1

(age < 18 months)

  • In-home visits every 2 months
  • Clinic assessments every 6 months
Cohort 2

(age ≥ 18 months - 3 years)

  • In-home visits every 4 months
  • Clinic assessments every 6 months
Cohort 3

(age > 3 - 5 years)

  • In-home visits every 6 months
  • Clinic assessments every 6 months
Cohort 4

(age > 5 years)

  • In-home visits every 12 months
  • Clinic assessments every 12 months
Cohort 5

(deceased)

• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.




Primary Outcome Measures :
  1. To characterize the natural history of Canavan disease [ Time Frame: up to 3 years ]
    To enhance the understanding of the natural history of Canavan disease through retrospective data collection from patient medical records and prospective data collection from living patients, including: Phenotypic characteristics and variability, Genotype


Biospecimen Retention:   Samples With DNA
Hematology, blood chemistry, urinalysis, genetic mutation confirmation, antibody testing


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Living and deceased patients with Canavan disease
Criteria

Inclusion Criteria:

  1. Meet age criteria of a specific cohort.*
  2. Confirmed clinical and biochemical diagnosis of Canavan disease before age 18 months.
  3. Available medical records since birth that permit documentation of disease characteristics and developmental milestones.
  4. Parent and/or legal guardian is able to read, understand, and sign the informed consent.

    • In the case of a deceased patient whose parent(s) and/or legal guardian(s) have provided informed consent for study participation, the Investigator will review the patient's medical record(s) to determine study eligibility.

Exclusion Criteria:

1. Patient does not meet the Inclusion Criteria.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04126005


Contacts
Layout table for location contacts
Contact: Kathleen M Kirby 978-479-7640 kmk@bridgebio.com

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Haley Andonian    617-724-1379    HANDONIAN@mgh.harvard.edu   
Principal Investigator: Florian Eichler, MD         
United States, New York
NYU Langone Medical Center Recruiting
New York, New York, United States, 10016
Contact: Danika Anganoo-Khan    929-455-5629    Danika.Anganoo-Khan@nyulangone.org   
Principal Investigator: Heather Lau, MD         
Germany
University Medical Center Hamburg-Eppendorf Not yet recruiting
Hamburg, Germany, 20246
Contact: Christine Fehrs    0049(0) 40 7410- 59060    c.fehrs@uke.de   
Principal Investigator: Annette Bley, MD         
Sponsors and Collaborators
Aspa Therapeutics

Additional Information:
Layout table for additonal information
Responsible Party: Aspa Therapeutics
ClinicalTrials.gov Identifier: NCT04126005     History of Changes
Other Study ID Numbers: CVN-101
First Posted: October 14, 2019    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data will be made available for researchers using a defined process.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aspa Therapeutics:
Canavan Disease
leukodystrophy
natural history
non-interventional
Additional relevant MeSH terms:
Layout table for MeSH terms
Canavan Disease
Hereditary Central Nervous System Demyelinating Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Demyelinating Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Metabolic Diseases
Leukoencephalopathies
Metabolism, Inborn Errors